# Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

> **NCT06680115** · PHASE2 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 150 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06680115
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2026-12
- **Final completion:** 2029-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680115, "Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06680115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*